PDCD1 and neoplasm: Moreover, this therapy sensitized the tumor for anti-PD-1 and anti-CTLA-4 antibodies, since the combination therapy led to an increased tumor regression and prolonged mouse survival as compared to the therapy with ICI alone (92).